These pathways were not enriched in the HepG2 tumor sample, although four were increased in the HepG2 cell sample (TNFα signaling via NFκB, allograft rejection, IL-6/JAK/STAT3 signaling, inflammatory response) (Fig. 5b). The gene discussed is STAT3; the disease is neoplasm.